Traditional Chinese medicine composition for improving sleep as well as preparation method and application of traditional Chinese medicine composition
Through traditional Chinese medicine compositions, including jujube seeds, longan meat, wolfberry, poria, lily, light bamboo leaves and black dates or jujubes, it is prepared by solvent extraction method, and the problem of failure to improve sleep through food in the prior art is solved, and the problem of failure to improve sleep through food is achieved. Effective improvement of insomnia caused by qi and blood deficiency and reversal of neuroinflammation.
Patent Information
- Application Number
- CN202410898995.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has failed to effectively improve sleep problems through food, especially for insomnia caused by qi and blood deficiency, and the development of drugs focuses on drugs rather than food.
Provided is a traditional Chinese medicine composition, including jujube seeds, longan meat, wolfberry, poria, lily, light bamboo leaves and black dates or jujubes, which are prepared by solvent extraction method, for preparing food or drugs to improve sleep and regulate central nervous system transmission. and cytokines, reverse neuroinflammatory-related signaling pathways.
This traditional Chinese medicine composition can improve sleep quality, reverse the damage of astrocytes and microglia, regulate neurovascular inflammation and neurodegenerative diseases, and is suitable for sleep disorders caused by qi and blood deficiency. It can calm the mind and help sleep and reverse the Effects of inflammatory response.
Smart Images

Figure CN118903328A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for improving sleep, and a preparation method and application thereof. Background Art
[0002] With the rapid changes and development of social economy, competition is constantly intensifying, mental and physical exhaustion is increasing, anxiety is increasing, and people's insomnia problem is becoming more and more serious. Although there are many factors that affect sleep, Chinese medicine believes that the reason for affecting sleep is that "Yin does not restrain Yang" leads to "Yang does not enter Yin", liver blood is insufficient, the soul is not at home, the mind is uneasy, and the heart is restless and insomnia. Based on the theory of Chinese medicine, foods made from Chinese medicinal materials with the same origin as medicine and food, which have the effects of calming the mind and improving sleep, can improve sleep through food supplements.
[0003] Insomnia is a type of sleep disorder, characterized by frequent and persistent difficulty falling asleep or staying asleep, leading to sleep disorders. Modern medical research shows that sleep-wake alternation occurs under the regulation of central neurotransmitter factors such as the hypothalamus-pituitary-adrenal axis, dopamine, 5-hydroxytryptamine, neuropeptides, acetylcholine, γ-aminobutyric acid, and hormone regulatory factors such as melatonin and prostaglandin D2, as well as cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor. If these factors are abnormal, insomnia may also occur.
[0004] In recent years, overcoming sleep problems has mainly focused on the research and development of drugs, and no attention has been paid to improving sleep problems through food. To this end, the present invention provides a Chinese medicine composition for improving sleep and a preparation method and application thereof, providing a scientific and reasonable medicine and food prescription to nourish the body with food and solve sleep disorders. Summary of the invention
[0005] Therefore, the technical problem to be solved by the present invention is to provide a Chinese medicine composition for improving sleep and a preparation method and application thereof.
[0006] The invention provides a Chinese medicine composition for improving sleep, comprising the following components in parts by weight: 1-10 parts of sour jujube seeds, 1-8 parts of longan pulp, 1-8 parts of wolfberry, 1-10 parts of tuckahoe, 1-6 parts of lily, 1-4 parts of lophatherum gracile, 0-10 parts of black dates, and 0-10 parts of jujubes, wherein the weight parts of black dates and jujubes are not both 0 parts.
[0007] In some embodiments, the Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of Chinese jujube kernels, 1-8 parts of longan pulp, 2-10 parts of jujubes, 1-8 parts of wolfberries, 2-10 parts of Poria cocos, 1-6 parts of lilies, and 1-4 parts of lophatherum gracile.
[0008] In some embodiments, the Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of Chinese jujube kernels, 1-8 parts of longan pulp, 2-10 parts of black dates, 1-8 parts of wolfberries, 2-10 parts of Poria cocos, 1-6 parts of lilies, and 1-4 parts of lophatherum gracile.
[0009] In some embodiments, the Chinese medicine composition comprises the following components in parts by weight: 4-6 parts of Chinese jujube seeds, 3-5 parts of longan pulp, 3-6 parts of jujube, 3-5 parts of wolfberry, 3-6 parts of Poria cocos, 2-4 parts of lily, and 1-3 parts of lophatherum gracile.
[0010] On the other hand, the preparation method of the Chinese medicine composition for improving sleep provided by the present invention comprises the following steps: weighing each component according to the formula to obtain a mixture, using a solvent extraction method to obtain a supernatant, and performing solid-liquid separation to obtain the Chinese medicine composition.
[0011] In some embodiments, the solvent extraction method includes the steps of soaking the mixture with an extraction solvent; or, adding an extraction solvent to the mixture for at least one extraction to obtain an extract, concentrating the extract to obtain a clear paste, adding an extraction solvent to the clear paste, and letting it stand.
[0012] In some of the embodiments, the method for preparing the Chinese medicine composition further comprises the step of freeze-drying the Chinese medicine composition to obtain a freeze-dried powder of the Chinese medicine composition.
[0013] The mass ratio of the mixture to the extraction solvent is (2-7): (100-600).
[0014] Optionally, the extraction solvent comprises ethanol.
[0015] Optionally, the soaking time is greater than or equal to 15 days.
[0016] In some embodiments, the step of soaking the mixture with an extraction solvent further comprises a circulation step, and the frequency of the circulation is 1 to 2 times per day.
[0017] Optionally, the circulation step specifically includes circulating the extraction solvent wine from the bottom of the tank into the top of the tank
[0018] In some embodiments, the volume concentration of the extraction solvent in the soaking mixture is 20% to 75%.
[0019] In some of the embodiments, the freeze-drying time is 8 to 24 hours, the vacuum degree is -0.10 to -0.05 MPa, and the cold trap temperature is -80 to -40°C.
[0020] In some embodiments, the volume concentration of the extraction solvent added to the mixture is 30% to 95%.
[0021] In some of the embodiments, during a single extraction, the mass ratio of the extraction solvent added to the mixture to the mixture is (4-10):1.
[0022] In some embodiments, the extraction method comprises a heating reflux method.
[0023] Optionally, the time for a single extraction is 0.45 to 2 hours.
[0024] In some embodiments, the method of concentrating comprises concentrating under reduced pressure.
[0025] In some of the embodiments, the relative density of the clear paste is 1.15-1.25.
[0026] In some of the embodiments, an extraction solvent is added to the clear paste to adjust the alcohol content of the clear paste to 20-56%, Vol.
[0027] In some embodiments, the standing time is greater than or equal to 24 hours.
[0028] Solid-liquid separation includes the step of filtration.
[0029] The Chinese medicine composition for improving sleep provided by the present invention or the Chinese medicine composition prepared by the preparation method of the Chinese medicine composition for improving sleep is suitable for people suffering from insomnia caused by deficiency of both qi and blood. Such people have sallow complexion, are prone to fatigue, often feel tired, have chaotic thoughts after insomnia, have various dreams at night, often stay up late, overuse their eyes, etc. The present invention is made into a beverage wine, which is suitable for ordinary people to drink in the cold seasons of spring and winter, and is used for daily health care, and patients suffering from insomnia due to deficiency of both qi and blood can drink it at any time of the year.
[0030] The Chinese medicine composition for improving sleep provided by the present invention or the Chinese medicine composition prepared by the preparation method of the Chinese medicine composition for improving sleep has any of the following uses:
[0031] (1) Prepare foods and medicines for improving sleep and treating deficiency of Qi and blood; optionally, the foods include alcoholic beverages; optionally, the medicines include at least one of capsules, tablets, granules, powders, pills, oral liquids or suspensions; (2) Reverse damage and aging of astrocytes and microglia; (3) Reverse inflammatory responses; (4) Regulate circadian rhythms; (5) Reverse pathways related to neurodegeneration, neuroinflammation, neuronal excitation and peripheral inflammation.
[0032] Optionally, the reversal pathway includes at least one of a neurodegenerative pathway - multiple diseases, Alzheimer's disease, Parkinson's syndrome, neuroactive ligand-receptor interaction, cytokine-cytokine receptor interaction, cell autophagy, ATP metabolism, TNF signaling pathway, NOD-like receptor signaling, cell adhesion, cell apoptosis, and cell aging pathway.
[0033] The technical solution of the present invention has the following advantages:
[0034] 1. The Chinese medicine composition for improving sleep provided by the present invention comprises the following components in parts by weight: 1-10 parts of sour jujube seeds, 1-8 parts of longan pulp, 1-8 parts of wolfberry, 1-10 parts of poria, 1-6 parts of lily, 1-4 parts of loquat leaf, 0-10 parts of black dates, and 0-10 parts of jujube, wherein the weight parts of black dates and jujube are not both 0 parts. The present invention adopts the medicinal flavor of medicine and food as the formula raw material, and according to the TCM theory of monarch, minister, assistant and messenger, a Chinese medicine composition capable of improving sleep is prepared by scientifically allocating the formula ratio, wherein the Chinese jujube seeds nourish the heart and liver, calm the mind and soothe the nerves, the longan meat nourishes the heart and spleen, nourishes blood and soothes the nerves, and the two medicines are soothing the nerves and helping sleep as the monarch medicine; the jujube nourishes the middle and replenishes qi, nourishes blood and soothes the nerves, the black date nourishes the liver and kidney, moisturizes dryness and produces body fluid, the wolfberry nourishes the liver and kidney, the tuckahoe invigorates the spleen and soothes the heart, the lily nourishes yin and moistens the lungs, clears the heart and soothes the nerves, and the four medicines are qi-invigorating, yin-nourishing and blood-nourishing, so that the qi and blood are full, and the mind is self-calming as the minister medicine; the light bamboo leaf clears away heat and purges fire, eliminates restlessness and quenches thirst, counter-assists the monarch and minister that are relatively warm, and has the effect of eliminating restlessness and soothing the nerves as the adjuvant medicine. The whole recipe nourishes qi and blood, calms the nerves and helps sleep, and is suitable for people with sleep disorders caused by qi and blood deficiency.
[0035] 2. The preparation method of the Chinese medicine composition for improving sleep provided by the present invention comprises the following steps: weighing each component according to the formula to obtain a mixture, using a solvent extraction method to obtain a supernatant, and performing solid-liquid separation to obtain a Chinese medicine composition. The solvent extraction method used in the present invention can effectively ensure the content of spinosin and total flavonoids in the Chinese medicine composition, so as to improve the effect of the Chinese medicine composition on improving sleep quality.
[0036] 3. The present invention provides a Chinese medicine composition for improving sleep or a Chinese medicine composition prepared by a method for preparing a Chinese medicine composition for improving sleep, which has the following uses, including preparing food and medicine for improving sleep and qi and blood deficiency; reversing damage to astrocytes and microglia; reversing nerve and inflammation-related signal pathways; regulating neurovascular inflammation and neurodegenerative diseases. The present invention uses a high-throughput Chinese medicine activity screening technology of transcriptome sequencing and a bioinformatics method to perform data analysis on the expression spectrum of the Chinese medicine composition, obtains a specific gene expression map and a signal pathway map of the Chinese medicine composition, and proves that the Chinese medicine composition obtained by the present invention can reverse nerve and inflammation-related signal pathways, reverse damage to astrocytes and microglia, and can regulate neurovascular inflammation and neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0038] Figure 1 It is a differential gene cluster diagram of the drug administration group and the HMC3 cell model group in Experimental Example 3 of the present invention;
[0039] Figure 2 This is a KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HMC3 cell model group in Experimental Example 3 of the present invention;
[0040] Figure 3 This is a GSEA-GOBP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HMC3 cell model group in Experimental Example 3 of the present invention;
[0041] Figure 4 This is a GSEA-KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HMC3 cell model group in Experimental Example 3 of the present invention;
[0042] Figure 5 It is a differential gene cluster diagram of the drug administration group and the U251 cell model group in Experimental Example 3 of the present invention;
[0043] Figure 6 This is a GO-BP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the U251 cell model group in Experimental Example 3 of the present invention;
[0044] Figure 7 This is a GSEA-GOBP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the U251 cell model group in Experimental Example 3 of the present invention;
[0045] Figure 8 This is a GSEA-KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the U251 cell model group in Experimental Example 3 of the present invention;
[0046] Fig. 9 The differential gene clusters of the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention are Figure 1 ;
[0047] Fig.10 The differential gene clusters of the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention are Figure 2 ;
[0048] Fig.11 The differential gene clusters of the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention are Figure 3 ;
[0049] Fig.12 The differential gene clusters of the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention are Figure 4 ;
[0050] Fig.13 This is a GO-BP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention;
[0051] Fig.14 This is a KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention;
[0052] Fig.15 This is a GSEA-KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the SH-SY5Y cell model group in Experimental Example 3 of the present invention;
[0053] Fig.16 is a differential gene clustering diagram of the drug administration group and the HUVEC-T1 cell model group in Experimental Example 3 of the present invention;
[0054] Fig.17 This is a GO-BP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HUVEC-T1 cell model group in Experimental Example 3 of the present invention;
[0055] Fig.18 This is a KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HUVEC-T1 cell model group in Experimental Example 3 of the present invention;
[0056] Fig.19 This is a GSEA-GOBP pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HUVEC-T1 cell model group in Experimental Example 3 of the present invention;
[0057] Fig. 20 This is a GSEA-KEGG pathway enrichment analysis diagram of differentially expressed genes between the drug administration group and the HUVEC-T1 cell model group in Experimental Example 3 of the present invention. DETAILED DESCRIPTION
[0058] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the guidance of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0059] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.
[0060] Example 1
[0061] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0062] Weigh 6g of sour jujube kernel, 4g of longan pulp, 2g of jujube, 2g of wolfberry, 3g of poria, 2g of lily bulb, and 1g of lophatherum gracile.
[0063] Put the above materials into an extraction tank, add 1500g of white wine to soak the medicinal materials, wherein the volume concentration of ethanol in the white wine is 56%, and soak for 30 days at 25°C. During the soaking process, circulate once a day. The circulation must ensure that the white wine in the extraction tank can be completely circulated at least once. The circulation step is to circulate the white wine from the bottom of the tank through the top of the tank and inject it into the extraction container. After the soaking is completed, discard the residue and filter to obtain the Chinese medicine composition.
[0064] Example 2
[0065] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0066] Weigh 6g of sour jujube kernel, 4g of longan pulp, 2g of jujube, 2g of wolfberry, 3g of poria, 2g of lily bulb, and 1g of lophatherum gracile.
[0067] The above materials are placed in an extraction tank, and 8 times the volume concentration of 70% ethanol solution, i.e. 160g of 70% ethanol solution is added. After heating and refluxing for 1h, the mixture is passed through an 80-mesh sieve to collect the extract. Then, 6 times the volume concentration of 70% ethanol solution, i.e. 120g of 70% ethanol solution is added thereto. After heating and refluxing for 1h, the mixture is passed through an 80-mesh sieve to collect the extract. The two extracts are combined, and the extract is concentrated under reduced pressure to a relative density of 1.2 to obtain a clear paste. The clear paste is mixed with edible alcohol and pure water, and the alcohol content of the mixture is adjusted to 35%, Vol., and stirred evenly. The mixture is allowed to stand for 24h, the supernatant is absorbed, and the residue is filtered to obtain a Chinese medicine composition.
[0068] Example 3
[0069] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0070] The traditional Chinese medicine composition prepared in Example 1 was freeze-dried at a cold trap temperature of -40°C and a vacuum degree of -0.08 MPa for 20 hours to obtain a powder of the traditional Chinese medicine composition.
[0071] Example 4
[0072] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0073] Weigh 1g of sour jujube kernel, 8g of longan pulp, 10g of black dates, 8g of wolfberry, 1g of poria, 6g of lily bulb, and 4g of lophatherum gracile.
[0074] Put the above materials into an extraction tank, add 6000g of white wine to soak the medicinal materials, wherein the volume concentration of ethanol in the white wine is 20%, soak for 15 days at 25°C, circulate twice a day during the soaking process, and the circulation must ensure that the white wine in the extraction tank can be completely circulated at least once, wherein the circulation step is to circulate the white wine from the bottom of the tank through the top of the tank and inject it into the extraction container. After the soaking is completed, discard the residue and filter to obtain the Chinese medicine composition.
[0075] The prepared traditional Chinese medicine composition was freeze-dried at a cold trap temperature of -80°C and a vacuum degree of -0.10 MPa for 8 hours to obtain a powder of the traditional Chinese medicine composition.
[0076] Example 5
[0077] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0078] Weigh 10g of sour jujube kernel, 1g of longan pulp, 2g of black dates, 3g of jujube, 1g of wolfberry, 10g of poria, 1g of lily bulb, and 1g of lophatherum gracile.
[0079] Put the above materials into an extraction tank, add 1000g of white wine to soak the medicinal materials, wherein the volume concentration of ethanol in the white wine is 75%, and soak for 35 days at 25°C. During the soaking process, circulate twice a day. The circulation must ensure that the white wine in the extraction tank can be completely circulated at least once. The circulation step is to circulate the white wine from the bottom of the tank through the top of the tank and inject it into the extraction container. After the soaking is completed, discard the residue and filter to obtain the Chinese medicine composition.
[0080] The prepared traditional Chinese medicine composition was freeze-dried at a cold trap temperature of -40°C and a vacuum degree of -0.05 MPa for 24 hours to obtain a powder of the traditional Chinese medicine composition.
[0081] Example 6
[0082] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0083] Weigh 2g of sour jujube kernel, 5g of longan pulp, 2g of jujube, 3g of wolfberry, 6g of poria, 4g of lily bulb, and 3g of lophatherum gracile.
[0084] The above materials are placed in an extraction tank, and 8 times the volume concentration of 30% ethanol solution is added. After heating and reflux for 0.45h, the mixture is passed through an 80-mesh sieve to collect the extract. Then, 10 times the volume concentration of 95% ethanol solution is added thereto, and the mixture is heated and refluxed for 2h, and the extract is passed through an 80-mesh sieve to collect the extract. The two extracts are combined, and the extract is concentrated under reduced pressure to a relative density of 1.25 to obtain a clear paste. The clear paste is mixed with edible alcohol and pure water, and the alcohol content of the mixture is adjusted to 20%, Vol. After stirring evenly, the mixture is allowed to stand for 24h, the supernatant is absorbed, and the filter residue is filtered to obtain a traditional Chinese medicine composition.
[0085] Example 7
[0086] This embodiment provides a method for preparing a Chinese medicine composition for improving sleep, and the specific steps and parameters are as follows:
[0087] Weigh 4g of sour jujube kernel, 3g of longan pulp, 10g of jujube, 3g of wolfberry, 2g of poria, 4g of lily bulb, and 3g of lophatherum gracile.
[0088] The above materials are placed in an extraction tank, and 6 times the volume concentration of 95% ethanol solution is added. After heating and reflux for 1.5 hours, the mixture is passed through an 80-mesh sieve to collect the extract. Then 4 times the volume concentration of 70% ethanol solution is added thereto, and the mixture is heated and refluxed for 0.8 hours, the extract is passed through an 80-mesh sieve to collect the extract. The two extracts are combined, and the extract is concentrated under reduced pressure to a relative density of 1.15 to obtain a clear paste. The clear paste is mixed with edible alcohol and pure water, and the alcohol content of the mixture is adjusted to 56%, Vol. After stirring evenly, the mixture is allowed to stand for 24 hours, the supernatant is absorbed, and the residue is filtered to obtain a traditional Chinese medicine composition.
[0089] Experimental Example 1
[0090] The spinosum content of the traditional Chinese medicine composition prepared in Example 1 was measured, and the measurement results are shown in Table 1.
[0091] Determination method of spinosum content:
[0092] (1) Chromatographic conditions and system suitability test: Octadecylsilane bonded silica gel was used as filler, acetonitrile-water (15:85, v / v) was used as mobile phase; flow rate was 1.0 ml / min; column temperature was 25°C; detection wavelength was 335 nm. The theoretical plate number calculated based on the spinosin peak should be no less than 2000.
[0093] (2) Preparation of reference solution: Take an appropriate amount of spinosum reference substance, accurately weigh it, and add methanol to make a solution with a mass concentration of 60 μg / mL to obtain the reference solution.
[0094] (3) Preparation of the test solution: accurately measure 100 mL of the Chinese medicine composition prepared in Example 1, place it in an evaporating dish, evaporate it in a water bath until it is almost dry, add a small amount of dilute ethanol to dissolve it, transfer it to a 25 mL volumetric flask, add dilute ethanol to make the volume up to 25 mL, shake well, filter, and take the filtrate to obtain the test solution.
[0095] (4) Determination: Accurately pipette 10 μL of the reference solution and the test solution respectively, inject into the liquid chromatograph to obtain the spinosum content, wherein three samples of the test solution are taken.
[0096] Table 1 Test results of spinosum content in the Chinese medicine composition prepared in Example 1
[0097] Sample No. Spinosin content (μg / mL) 1 3.08 2 3.01 3 2.93
[0098] It can be seen that the content of spinosum in the traditional Chinese medicine composition prepared in Example 1 of the present invention is 2.93-3.08 μg / mL.
[0099] Experimental Example 2
[0100] The total flavonoid content of the traditional Chinese medicine composition prepared in Example 1 was measured, and the measurement results are shown in Table 2.
[0101] Determination method of total flavonoids content:
[0102] (1) Preparation of reference solution: Accurately weigh 10 mg of rutin reference substance and place it in a 50 ml volumetric flask. Add an appropriate amount of dilute ethanol and sonicate to dissolve the rutin reference substance. Allow to cool and add dilute ethanol to make up to 50 ml. Shake well to obtain a reference solution containing 0.20 mg / ml rutin.
[0103] (2) Preparation of standard curve: Accurately measure 0 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml and 6 ml of the reference solution and place them in 25 ml volumetric flasks respectively. Add water to 6 ml each time, add 1 ml of 5% sodium nitrite solution, shake well, let stand for 6 minutes, add 1 ml of 10% aluminum nitrate solution, shake well, let stand for 6 minutes, add 10 ml of 5% sodium hydroxide solution, add water to make up to 25 ml, shake well, let stand for 15 minutes, use 0 ml as blank, and immediately measure the absorbance at a wavelength of 510 nm according to the UV-Vis spectrophotometry (General Rule 0401). Draw a standard curve with absorbance (A) as the ordinate and concentration (C) as the abscissa.
[0104] (3) Assay method: Accurately measure 100 ml of the Chinese medicine composition prepared in Example 1 into an evaporating dish, evaporate it in a water bath until it is nearly dry (about 1-2 ml remaining), cool it, add a small amount of dilute ethanol to dissolve it, transfer it to a 25 ml volumetric flask, add dilute ethanol to make up to 25 ml, shake well, and obtain the test solution. Accurately measure 5 ml of the test solution into a 25 ml volumetric flask. According to the method for preparing the standard curve in step (2) of this experimental example, add water to the 25 ml volumetric flask to make up to 6 ml. Add 1 ml of 5% sodium nitrite solution, shake well, and let stand for 6 minutes. Add 1 ml of 10% aluminum nitrate solution, shake well, and let stand for 6 minutes. Add 10 ml of 5% sodium hydroxide solution, add water to make up to 25 ml, shake well, and let stand for 15 minutes. Immediately measure the absorbance at a wavelength of 510 nm according to the UV-Vis spectrophotometry (General Rule 0401). Read the concentration of rutin in the test solution from the standard curve and calculate to obtain, wherein three samples are taken.
[0105] Table 2 Test results of total flavonoid content of the Chinese medicine composition prepared in Example 1
[0106]
[0107]
[0108] It can be seen that the total flavonoid content of the traditional Chinese medicine composition prepared in Example 1 of the present invention is 42.63-44.89 μg / mL.
[0109] Experimental Example 3
[0110] The enrichment of the Chinese medicine composition prepared in Example 1-2 and the positive control drug γ-aminobutyric acid in different cell line signal channels was detected and analyzed, and the specific steps were as follows:
[0111] 3.1 Determination of the in vitro cytotoxicity of the Chinese medicine composition prepared in Example 1-2 on different cell lines:
[0112] 3.1.1 The cells were modeled according to the modeling conditions in Table 3 to construct a vascular microglial inflammation model (HMC3 cell model), an astrocyte inflammation model (U251 cell model), a neuronal cell excitation model (SH-SY5Y cell model), and a vascular endothelial cell inflammation model (HUVEC-T1 cell model).
[0113] Table 3 Cell lines and modeling conditions
[0114] Cell Name Cell source Modeling agent Modeling agent concentration Processing time HMC3 Human microglia IL1β 5ng / mL 24h U251 Human astrocytes LPS 100ng / mL 24h SH-SY5Y Human neuronal cells Glutamate 1 μg / mL 24h HUVEC-T1 Human vascular endothelial cells IL1β 5 ng / mL 24h
[0115] 3.1.2 The CCK-8 (Cell Counting Kit-8) cytotoxicity detection kit was used to detect the in vitro cytotoxicity of the Chinese medicine composition prepared in Example 1 and Example 2 and the positive control drug γ-aminobutyric acid on the vascular microglial inflammation model, astrocyte inflammation model, neuronal cell excitement model, and vascular endothelial cell inflammation model. The cytotoxicity detection method was performed in accordance with the Bimake Cell Counting Kit-8 kit instructions.
[0116] 3.1.3 The results showed that the Chinese medicine compositions prepared in Example 1 and Example 2 had no obvious cytotoxicity to the HMC3 cell model, U251 cell model, SH-SY5Y cell model, and HUVEC-T1 cell model at a concentration range of 2.5-1280 μg / mL; the positive control drug γ-aminobutyric acid had no obvious cytotoxicity to the HMC3 cell model, U251 cell model, SH-SY5Y cell model, and HUVEC-T1 cell model at a molar concentration range of 2.5 nM-200 μM.
[0117] 3.2 Determination of genetic differences between the drug-treated group and the HMC3 cell model
[0118] 3.2.1 The Chinese medicine composition prepared in Example 1 and the positive control drug γ-aminobutyric acid were respectively added to the well plate cultured with the HMC3 cell model, placed in a 37°C constant temperature incubator for 24 hours, the well plate was taken out of the incubator, the culture medium in the well plate was discarded, and the plate was washed once with phosphate buffered saline (PBS) to obtain a lysate, and the lysate was added to the experimental sample wells to lyse the cells on ice for 5 minutes. The cells were observed to be completely lysed under a microscope, and the samples of each group were collected. Among them, the experimental group in which Example 1 and the positive control drug γ-aminobutyric acid were administered to the model cells was the administration group, Specifically, the final concentration of the Chinese medicine composition prepared in Example 1 was 25 μg / mL for dosing group 1, the final concentration of the Chinese medicine composition prepared in Example 1 was 100 μg / mL for dosing group 2, the final concentration of the Chinese medicine composition prepared in Example 1 was 400 μg / mL for dosing group 3, and the final concentration of the positive control drug γ-aminobutyric acid was 80 nM for dosing group 4. The Chinese medicine compositions of the above dosing groups used 50% DMSO by volume as a solvent to prepare agents of different concentrations, the unadministered HMC3 cell model was the model group, and samples from each group were sent for high-throughput sequencing.
[0119] 3.2.2 The original sequence was filtered using the software Trimmomatic (version 0.36) to obtain high-quality CleanReads, and HISAT2 (version 2.1.0) and StringTie (version 1.3.5) software were used for alignment. The alignment results reflect the specific location of the sample data in the reference genome. The DESeq (version 1.39.0) software package was used to screen the intersection genes between the drug treatment group and the model group with the differential expression multiple greater than 1.5 and p.value < 0.05 as the conditions for passing the significance test, and a heat map of differential genes was drawn, see Figure 1 From Table 4, it can be seen that the Chinese medicine composition prepared in Example 1 of the present invention has a certain reversal effect on the expression of differentially expressed genes in the model group at different concentrations.
[0120] Among them, the filtering criteria for the original data are:
[0121] a. If the reads contain adapter sequences, the adapter sequences are truncated first: 2 base mismatches are allowed;
[0122] b. Using a sliding window of 4 bases in length, remove bases with an average base quality of less than 15 at both ends of the reads;
[0123] c. Remove bases with quality values lower than 15 from the beginning and end of the reads respectively until one base reaches a quality value of 15;
[0124] d. If the length of the truncated reads is less than 50 bp, the entire pair of reads is removed;
[0125] e. Remove unpaired reads.
[0126] Table 4 Gene reversal number in drug administration group (HMC3)
[0127]
[0128] 3.2.3 KEGG pathway enrichment analysis was performed on the differentially expressed genes in the drug-treated groups using the KEGG database to screen for significantly enriched (p.value < 0.05) KEGG pathways. Figure 2The results show that there are 19 pathways that affect the model group and each drug-treated group (p.value<0.05). Among them, the drug-treated group 3 with a final concentration of 400 μg / mL of the Chinese medicine composition prepared in Example 1 has the largest number of enriched pathways, and the differentially expressed genes are significantly enriched in the interaction between cytokines and cytokine receptors (cytokine-cytokine receptor interaction), NF-κB signaling pathway (NF-kappa b signaling pathway), and IL-17 signaling pathway (IL-17signaling pathway).
[0129] 3.2.4 GSEA (version number: 3.0) data analysis was used to perform GOBP pathway analysis on the differentially expressed genes in the drug-treated groups, and the GSEA-GOBP pathways with significant enrichment (FDR < 0.25) were screened, and the pathways related to nerves and inflammation were screened for mapping, such as Figure 3 As shown, it can be seen that each drug-treated group has a certain reversal effect on the dysregulated signaling pathways, including ATP biosynthetic process, ATP metabolic process, etc., more specifically, including the regulation of gamma-aminobutyric acid secretion, the regulation of dopamine secretion, the regulation of catecholamine secretion and other neurotransmitter-related pathways, neuroinflammatory response, glial cell activation, positive regulation of interleukin-1beta production, positive regulation of interleukin-1 production, positive regulation of IL-6 production and other neuroinflammatory-related pathways.
[0130] 3.2.5 GSEA technology was used to perform GSEA-KEGG pathway analysis on the differentially expressed genes in the drug-treated groups using the KEGG database, and the GSEA-KEGG pathways with significant enrichment (p.value < 0.05 and FDR < 0.25) were screened, and the pathways related to nerves, neurodegeneration, immunity, cell survival, etc. were screened for mapping. Figure 4 As shown. The Chinese medicine composition prepared in Example 1 has a good reversal effect on neurodegenerative disease-related pathways, including neurodegenerative pathways-multiple diseases, Alzheimer's disease, Parkinson's disease, etc., and pathways such as neuroactive ligand-receptor interaction, cytokine-cytokinereceptor interaction, cell autophagy, cell apoptosis, and endocytosis are also reversed.
[0131] HMC3, derived from human microglia, is an immortalized cell line constructed by overexpressing the large T antigen gene SV40 in primary microglia. It is widely distributed throughout the brain and spinal cord and is a commonly used cell line for studying microglial function. It can regulate the secretion of soluble inflammatory mediators and is very important for maintaining the homeostasis of the nervous system. In this experimental example, interleukin-1β (IL1β) was used to treat cells to construct a vascular microglial inflammation model for evaluating the intervention effect of drugs on neuroinflammation. From the results, the sleep-inducing Chinese medicine composition prepared by the present invention has a certain anti-neuroinflammatory effect, in which the positive regulatory signal pathway produced by type I interferon is reversed. Studies have shown that the activation of type I interferon is closely related to neurodegenerative diseases including Alzheimer's disease. Long-term blockade of IFN-I receptors can reduce synaptic defects, microglial proliferation, and alleviate neuroinflammation (Roy ER, Chiu G, Li S, et al. Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid beta plaques. Immunity. 2022, 55(5): 879-894e876.). In addition, the autophagy signaling pathway (Autophagyanimal, Autophagy-other) was significantly reversed. Taking Parkinson's disease as an example, its main pathological feature is the accumulation of α-synuclein leading to polarization of microglia M1-like phenotype, and impaired autophagy and phagocytosis of microglia inducing neuroinflammatory response (Lv QK, Tao KX, Wang XB, et al. Role of alpha-synuclein inmicroglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease. Inflamm Res. 2023, 72(3): 443-462.).
[0132] 3.3 Determination of genetic differences between the drug-treated group and the U251 cell model
[0133] 3.3.1 Referring to the method in 3.2.1, the Chinese medicine composition prepared in Example 3 and the positive control drug γ-aminobutyric acid were respectively administered to U251 cells, and the cells were sent for sequencing according to the method in 3.2.1, wherein the administration group was the Chinese medicine composition prepared in Example 3 and γ-aminobutyric acid. Specifically, the Chinese medicine composition prepared in Example 3 with a final concentration of 400 μg / mL was administration group 1, and the γ-aminobutyric acid with a final concentration of 80 nM was administration group 2. The Chinese medicine composition in the above-mentioned administration groups used DMSO with a volume concentration of 50% as the solvent to prepare different concentrations of the drugs, and the model group was a U251 cell model without medication.
[0134] 3.3.2 Refer to the method in 3.2.2 to screen the intersection genes between each drug group and the model group and draw a differential gene heat map, see Figure 5 From Table 5, it can be seen that the Chinese medicine composition prepared in Example 3 and γ-aminobutyric acid both have a certain reversal effect on the expression of differentially expressed genes in the model group.
[0135] Table 5 Number of gene reversal in drug group (U251)
[0136]
[0137] 3.3.2 GO-BP pathway enrichment analysis was performed on the differentially expressed genes in the drug-treated groups in the GO database. There were 66 pathways affected by both the model group and each drug-treated group (p.value<0.05). The top 20 pathways were as follows: Figure 6 As shown, the Chinese medicine composition prepared in Example 3 can be significantly enriched in the regulation of acute inflammatory response and the positive regulation of acute inflammatory response, indicating that it has a certain regulatory effect on inflammatory response.
[0138] 3.3.3 GSEA technology was used to perform GSEA-GOBP pathway analysis on the differentially expressed genes in the drug-treated groups using the GO database, and the GSEA-GOBP pathways related to nerves, inflammation, etc. and significantly enriched (FDR < 0.25) were screened for mapping, such as Figure 7As shown, it can be seen that γ-aminobutyric acid can significantly reverse biological processes such as neuroinflammatory response, synaptic vesicle exocytosis, autophagy, and regulation of autophagy. The Chinese medicine composition prepared in Example 3 can significantly reverse biological processes such as ATP biosynthetic process, ATP metabolic process, neuron development, positive regulation of interleukin-8 production, and positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator.
[0139] 3.3.4 GSEA technology was used to perform GSEA-KEGG pathway analysis on the differential genes in the drug-treated groups in the KEGG database, and the GSEA-KEGG pathways with significant enrichment (FDR < 0.25) were screened, and the pathways related to nerves, inflammation, etc. were further screened for mapping, such as Figure 8 As shown, it can be seen that the group administered with the Chinese medicine composition prepared in Example 3 can significantly reverse neurodegenerative disease pathways such as neurodegeneration-multiple diseases and Alzheimer's disease, and pathways such as TNF signaling pathway, necrosis, cellular senescence, and endocytosis are also reversed.
[0140] A number of studies have shown that astrocytes are sleep-regulating cells and are an abundant cell type in the central nervous system. They are crucial for neurogenesis support, neuronal migration, ion regulation, synaptogenesis, neurotransmitter circulation and neuroendocrine function. Astrocyte damage is associated with the severity of insomnia and / or cognitive dysfunction (see Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005, 102(43): 15545-15550.). Neuroinflammation is usually spread through the activation of astrocytes and microglia, which is the main cause of neurodegeneration. At the same time, astrocytes have a powerful biological clock function. The loss of biological clock genes leads to significant activation of astrocytes in the body. The sleep-aiding and sleep-relief composition provided by the present invention can inhibit astrocyte activation, reduce neuroinflammatory response, and achieve the purpose of sleep-aiding and sleep-relief. The sleep-aiding and sleep-relief composition provided by the present invention can significantly enrich the AGE-RAGE signaling pathway, the metabolic pathways of glycine, serine and threonine, and play an important role in regulating neuronal excitability (Bowery NG, Smart TG. GABA and glycine as neurotransmitters: brief history. Br J Pharmacol. 2006, 147 Suppl 1 (Suppl 1): S109-S119). At the same time, supplementing glycine intake can improve the subjective sleep quality of people with insomnia (Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012, 118 (2): 145-148).Furthermore, ATP is the energy source of the brain nervous system, and changes in its content regulate the human sleep process (Dworak M, McCarley RW, Kim T, et al. Sleep and brain energy levels: ATP changes during sleep. J Neurosci. 2010, 30 (26): 9007-9016.). Studies have shown that extracellular ATP released by astrocytes can effectively mediate microglial activation, triggering the secretion of tumor necrosis factor-α (TNF-α) and interleukin-1β of activated microglia, thereby further aggravating the inflammatory response (Yin X, Feng L, Ma D, et al. Roles of astrocytic connexin-43, hemichannels, and gapjunctions in oxygen-glucose deprivation / reperfusion injury induced neuroinflammation and the possible regulatory mechanisms of salvianolic acid B and carbenoxolone. J Neuroinflammation. 2018, 15 (1): 97.), the sleep-aiding and sleep-relief composition provided by the present invention can inhibit the ATP biosynthesis process in astrocytes, thereby improving sleep disorders (Gudkov SV, Burmistrov DE, Kondakova EV, et al. An emerging role of astrocytes in aging / neuroinflammation and gut-brain axis with consequences on sleep and sleep disorders. Ageing Res Rev. 2023, 83: 101775.), in summary, the sleep-aiding and sleep-relief composition provided by the present invention has a certain effect of resisting astrocyte damage, thereby achieving the purpose of helping sleep and overcoming sleep disorders.
[0141] 3.4 Determination of genetic differences between the drug-treated group and the SH-SY5Y cell model
[0142] 3.4.1 Referring to the method in 3.2.1, the Chinese medicine composition prepared in Example 3 and the positive control drug γ-aminobutyric acid were respectively administered to SH-SY5Y cells, and each group of samples was sent for high-throughput sequencing, wherein the administration group was the Chinese medicine composition prepared in Example 3 and γ-aminobutyric acid, specifically, the Chinese medicine composition prepared in Example 3 with a final concentration of 100 μg / mL was administration group 1 and the γ-aminobutyric acid with a final concentration of 80 nM was administration group 2, and the model group was an SH-SY5Y cell model that was not administered.
[0143] 3.4.2 Refer to 3.2.2 method to screen the intersection genes of the drug group and the model group and draw a differential gene heat map, see Figure 9-12 From Table 6, it can be seen that both the Chinese medicine composition prepared in Example 3 and γ-aminobutyric acid have a certain reversal effect on the expression of differentially expressed genes in SH-SY5Y cells in the model group, and the reversal effect of the Chinese medicine composition prepared in Example 3 is better.
[0144] Table 6 Number of gene reversal in drug group (SH-SY5Y)
[0145]
[0146] 3.4.3 GO-BP pathway enrichment analysis was performed on the differentially expressed genes in each drug administration group in the GO database. Among them, there were 95 pathways affected by both the model group and each drug administration group (p.value<0.05). The top 20 pathways were as follows: Fig.13 As shown, the differentially expressed genes of the traditional Chinese medicine composition prepared in Example 3 can be significantly enriched in circadian rhythm, rhythmic process, trans-synaptic signaling, and regulating synaptic transmission, indicating that it has a certain regulatory effect on circadian rhythm and synaptic signaling.
[0147] 3.4.4 KEGG pathway enrichment analysis was performed on the differentially expressed genes in each drug group in the KEGG database. The results are shown in Fig.14 , among which, the model group and each drug-treated group affected a total of 8 pathways (p.value<0.05), among which, the Chinese medicine composition prepared in Example 2 can be significantly enriched in circadian rhythm, dopaminergic synapse, sphingolipid metabolism, MAPK signaling pathway and other signaling pathways, suggesting that the sleep-aiding wine may improve sleep by regulating the excitement of the nervous system.
[0148] 3.4.5 GSEA technology was used to perform GSEA-KEGG pathway analysis on the differentially expressed genes in the drug-treated groups in the KEGG database, and the GSEA-KEGG pathways with significant enrichment (FDR < 0.25) were screened for mapping. Fig.15 From the results of GSEA-KEGG analysis of all genes, it can be seen that the effect of the γ-aminobutyric acid reversal model group is slightly stronger, and the Chinese medicine composition prepared in Example 3 can significantly reverse the synaptic vesicle cycle, aminoacyl-tRNA biosynthesis, cytokine-cytokine receptor interaction, adherens junction and other pathways.
[0149] Glutamate is the main excitatory transmitter in the mammalian brain, and plays an important role in neurotransmission, differentiation and synaptic plasticity of the central nervous system. Studies have shown that the median concentration of glutamate increases significantly during sleep deprivation. The present invention uses glutamate to treat neuronal cells to simulate the state of neural excitation in the state of insomnia, and obtains the conclusion that the sleep-aiding and sleep-relief composition provided by the present invention has a certain reversal effect on the expression of differential genes in the model group. Among them, the sleep-aiding and sleep-relief Chinese medicine composition provided by the present invention can be significantly enriched in circadian rhythm, rhythmic process, transsynaptic signaling, and regulate synaptic transmission, dopaminergic synapses, sphingolipid metabolism, MAPK signaling pathways and other signaling pathways, suggesting that it has a certain regulatory effect on circadian rhythm and neural synaptic signaling. It can be seen that the sleep-aiding and sleep-relief Chinese medicine composition provided by the present invention achieves the effect of improving sleep by regulating the excitement of the nervous system. Furthermore, the sleep-aiding and sleep-relief Chinese medicine composition provided by the present invention can significantly reverse the synaptic vesicle cycle, the biosynthesis of aminoacyl-tRNA, the interaction between cytokines and cytokine receptors, and the adhesion connection pathways. Among them, synaptic vesicles are used to mediate communication between neurons through repeated exocytosis and endocytosis. Studies have shown that sleep deprivation can lead to impaired exocytosis and endocytosis of synaptic vesicles (Gulyássy P, Todorov- K, Tóth V, et al. The Effect of Sleep Deprivation and Subsequent Recovery Period on the Synaptic Proteome of Rat Cerebral Cortex. Mol Neurobiol. 2022, 59 (2): 1301-1319.), and in the present invention, it can be observed that the synaptic vesicle cycle is significantly downregulated in the neuronal excitation model induced by glutamate, proving that the Chinese medicine composition for helping sleep and sleeping provided by the present invention can significantly reverse the synaptic vesicle cycle pathway. In addition, the important composition for helping sleep and sleeping provided by the present invention can significantly reverse the interaction signal pathway between cytokines and cytokine receptors, improve synaptic vesicle circulation, and inhibit glutamate-induced neuroinflammatory response, thereby exerting a neuroprotective effect.
[0150] 3.5 Determination of genetic differences between the drug-treated group and the HUVEC-T1 cell model
[0151] 3.5.1 Referring to the method in 3.2.1, the Chinese medicine composition prepared in Example 3 and the positive control drug γ-aminobutyric acid were respectively applied to the HUVEC-T1 cell model, and each group of samples was sent for high-throughput sequencing. Among them, the experimental group in which the Chinese medicine composition prepared in Example 3 and the positive control drug γ-aminobutyric acid were administered to the model cells was the administration group, the Chinese medicine composition prepared in Example 3 with a final concentration of 400 μg / mL was the administration group 1, and the γ-aminobutyric acid with a final concentration of 80 nM was the administration group 2, and the model group was the HUVEC-T1 cell model without administration.
[0152] 3.5.2 Referring to the method in 3.2.2, the intersection genes of the drug administration group and the model group were screened and the differentially expressed genes were plotted, and Table 7 and Fig.16 It can be seen that the Chinese medicine composition and γ-aminobutyric acid prepared in Example 3 have different degrees of reversal effects on the expression of differentially expressed genes in the model group, among which inflammation-related genes such as IL1A and IL32 are significantly downregulated.
[0153] Table 7 Gene reversal number in drug group (HUVEC-T1)
[0154]
[0155] 3.5.3 GO-BP pathway enrichment analysis was performed on the differentially expressed genes in each drug-treated group in the GO database, and bubble charts were drawn for the top 20 pathways with significant effects (p.value < 0.05) between the model group and each drug-treated group. Fig.17Among them, the differentially expressed genes of the traditional Chinese medicine composition prepared in Example 3 can be significantly enriched in I-kappaB kinase / NF-kappaB signaling, stress-activated protein kinase signaling cascade, and cellular response to external stimulus, suggesting that it may have a certain anti-inflammatory effect.
[0156] 3.5.4 KEGG pathway enrichment analysis was performed on the differentially expressed genes in each medication group in the KEGG database, and a bubble diagram was drawn for the significantly affected pathways (p.value < 0.05) in the model group and the medication group of the Chinese medicine composition prepared in Example 3, see Fig.18 Among them, the differentially expressed genes of the traditional Chinese medicine composition prepared in Example 3 can be significantly enriched in inflammation and immune-related pathways such as MAPK signaling pathway, apoptosis, C-type lectin receptor signaling pathway, inflammatory mediator regulation of TRP channels, and AGE-RAGE signaling pathway in diabetic complications.
[0157] 3.5.5 GSEA technology was used to perform GSEA-GOBP pathway analysis on the GO database for differentially expressed genes in the drug-treated groups, and the significantly enriched (FDR < 0.25) GSEA-GOBP pathways were screened, and the neurovascular, inflammatory, and immune-related pathways were screened for mapping. Fig.19 It can be seen that γ-aminobutyric acid and the Chinese medicine composition prepared in Example 3 have a significant reversal effect on the related disordered pathways, among which the Chinese medicine composition prepared in Example 3 can significantly reverse NF-κB signaling, the response to tumor necrosis factor, apoptosis and autophagy related signaling pathways, and promote endothelial cell survival by improving amino acid metabolism, microtubule cytoskeleton and other pathways. γ-aminobutyric acid shows a stronger anti-inflammatory effect. In addition to the above-mentioned inflammatory pathways, it also has a strong reversal effect on cytokines, beta-amyloid protein, vascular development, and blood pressure regulation related signaling pathways.
[0158] 3.5.6 GSEA technology was used to perform GSEA-KEGG pathway analysis on the differentially expressed genes in the drug-treated groups in the KEGG database, and the GSEA-KEGG pathways with significant enrichment (FDR < 0.25) were screened for mapping. Fig. 20 It can be seen that the Chinese medicine composition prepared in Example 3 can reverse the overactivated TNF signaling pathway (TNF signalingpathway), Toll-like receptor signaling pathway (Toll-like receptor signaling pathway), NOD-like receptor signaling pathway (NOD-like receptor signaling pathway), TGF-β signaling pathway (TGF-betasignaling pathway) and other immune and inflammatory pathways in the HUVEC-T1 cell inflammation model. Pathways such as cell necrosis (Necroptosis), cell apoptosis (Apoptosis), cell autophagy (Autophagy-animal), and cell senescence (Cellular senescence) are also significantly reversed. At the same time, it also has a significant reversal effect on various neurodegenerative disease pathways such as Alzheimer's disease (Alzheimer disease) and Parkinson's syndrome (Parkinsondisease).
[0159] Modern pharmacological studies have confirmed that the regulation of sleep and circadian rhythm is related to the immune system and the release of inflammatory cytokines. Endothelial dysfunction has a bidirectional relationship with chronic inflammation. Chronic inflammation such as cardiovascular disease can lead to sleep disorders, and sleep disorders lead to increased inflammation levels (Irwin MR. Sleep and inflammation: partners insickness and in health. Nat Rev Immunol. 2019, 19(11): 702-715.). Sleep deprivation affects circadian rhythms and the balance of the autonomic nervous system, induces intravascular inflammatory responses and oxidative stress, and aggravates the occurrence of endothelial dysfunction (Cherubini JM, Cheng JL, Williams JS, et al. Sleep deprivation and endothelial function: reconciling seminal evidence with recent perspectives. Am J Physiol Heart Circ Physiol. 2021, 320(1): H29-H35.). The HUVEC-T1 cell line is a human umbilical vein endothelial cell transformed by SV40T, which is derived from the umbilical cord of a newborn and has the biological characteristics of human endothelial cells. It is a reliable model for scientific research in the field of cardiovascular and cerebrovascular diseases and is widely used in the study of the pathogenesis, preventive measures and treatment methods of cardiovascular and cerebrovascular diseases. The sleep-aiding and sleep-relief composition provided by the present invention significantly downregulates IL1A, IL32 and other inflammation-related genes, and can be significantly enriched in immune and inflammation-related molecular signaling pathways, including the AGE-RAGE signaling pathway in diabetic complications, inflammatory mediator regulation of TRP channels, cell apoptosis, cell senescence, etc., while the γ-aminobutyric acid group is more obviously enriched in amino acid metabolism-related pathways, such as alanine, aspartic acid and glutamate metabolism, valine, leucine and isoleucine degradation, cysteine and methionine metabolic pathways, and further, the sleep-aiding and sleep-relief composition provided by the present invention can reverse the multiple immune and inflammatory pathways overactivated in the model group, including TNF signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, TGF-β signaling pathway, etc.; At the same time, it can reverse the suppressed adhesion connection.It has been confirmed that insomnia can lead to increased levels of cerebrovascular inflammation (Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol. 2019, 19 (11): 702-715.), and excessive release of inflammatory factors can affect the normal respiration of cells, thereby generating reactive oxygen species that trigger peroxidation damage and subsequent inflammatory responses, leading to vascular endothelial dysfunction. The endothelial cell "adhesion connection" pathway involves adhesion between cells and between cells and the extracellular matrix, significantly affecting endothelial integrity. The sleep-aiding and sleep-relief composition provided in this application can reduce inflammatory responses and repair cell adhesion connections to improve sleep disorders.
[0160] 4. The reversal rate was calculated based on the GSEA-KEGG results, see Table 8.
[0161] Table 8 Chinese medicine composition, γ-aminobutyric acid GSEA-KEGG reversal rate
[0162]
[0163] Note: The above reversal rate results are obtained by statistics of GSEA-KEGG results shown in the report, wherein the HMC3 cell line is statistically analyzed excluding the insignificant pathways in the model group, and the Chinese medicine composition is the Chinese medicine composition prepared in Example 1.
[0164] It can be seen that the reversal rate of the traditional Chinese medicine composition prepared by the present invention in microglia, astrocytes and vascular endothelial cells is better than that of γ-aminobutyric acid.
[0165] In summary, the Chinese medicine composition prepared by the present invention has a certain reversal effect on the differential gene expression of the model group in the four disease-related cell models. Among them, in the neuroinflammation models such as HMC3 and U251, the differential genes can be significantly enriched in pathways such as acute inflammatory response, in the SH-SY5Y neuron excitation model, the differential genes can be significantly enriched in pathways such as circadian rhythm and synaptic transmission, and in the peripheral inflammatory pathways such as HUVEC-T1, the differential genes can be significantly enriched in pathways such as inflammatory mediator regulation of TRP channels and cell apoptosis. Therefore, the Chinese medicine composition prepared by the present invention has a certain effect of anti-neuroinflammation and regulating circadian rhythm.
[0166] At the same time, according to the GSEA analysis results, the Chinese medicine composition prepared by the present invention can significantly reverse the cytokine-cytokine receptor interaction, cell autophagy, ATP metabolism and other pathways in neuroinflammatory models such as HMC3 and U251, and can significantly reverse the cytokine-cytokine receptor interaction and other pathways in the SH-SY5Y neuron excitation model, and can significantly reverse the TNF signaling pathway, NOD-like receptor signaling pathway, cell adhesion, cell apoptosis, cell senescence and other pathways in peripheral inflammation models such as HUVEC-T1.
[0167] In summary, the traditional Chinese medicine composition prepared by the present invention can improve the ATP metabolism of microglia and astrocytes, inhibit neuroinflammatory response, improve the synaptic function of neuronal cells, inhibit the inflammatory response of vascular endothelial cells, improve interendothelial adhesion and connection, and resist aging.
[0168] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A Chinese medicine composition for improving sleep, characterized in that: The invention comprises the following raw materials in parts by weight: 1-10 parts of sour jujube kernels, 1-8 parts of longan pulps, 1-8 parts of wolfberries, 1-10 parts of poria cocos, 1-6 parts of lilies, 1-4 parts of lophatherum gracile, 0-10 parts of black dates, 0-10 parts of jujubes, wherein the weight parts of black dates and jujubes are different at the same time is 0 part.
2. The Chinese medicine composition for improving sleep according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 2-10 parts of sour jujube kernels, 1-8 parts of longan pulps, 2-10 parts of jujubes, 1-8 parts of wolfberries, 2-10 parts of poria cocos, 1-6 parts of lilies and 1-4 parts of lophatherum gracile.
3. The Chinese medicine composition for improving sleep according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 2-10 parts of sour jujube kernels, 1-8 parts of longan pulps, 2-10 parts of black dates, 1-8 parts of wolfberries, 2-10 parts of poria cocos, 1-6 parts of lilies and 1-4 parts of lophatherum gracile.
4. The Chinese medicine composition for improving sleep according to claim 2, characterized in that: The invention comprises the following raw materials in parts by weight: 4-6 parts of sour jujube kernels, 3-5 parts of longan pulps, 3-6 parts of jujubes, 3-5 parts of wolfberries, 3-6 parts of poria cocos, 2-4 parts of lilies and 1-3 parts of lophatherum gracile.
5. The method for preparing the Chinese medicine composition for improving sleep according to any one of claims 1 to 4, characterized in that: The following steps are included: The raw materials are weighed according to the formula to obtain a mixture, a solvent extraction method is used to obtain a supernatant, and solid-liquid separation is performed to obtain a traditional Chinese medicine composition.
6. The method for preparing the Chinese medicine composition for improving sleep according to claim 5, characterized in that: The solvent extraction method comprises the steps of soaking the mixture with an extraction solvent for soaking extraction; or, Add an extraction solvent to the mixture and perform heating reflux extraction at least once to obtain an extract, concentrate the extract to obtain a clear paste, add an extraction solvent to the clear paste, and let it stand.
7. The method for preparing the Chinese medicinal composition for improving sleep according to claim 6, characterized in that: In the soaking extraction step, the mass ratio of the mixture to the extraction solvent is (2-7): (100-600); and / or, In the soaking extraction step, the extraction solvent comprises ethanol; and / or, In the soaking and extraction step, the soaking time is ≥ 15 days; and / or, In the soaking extraction step, soaking the mixture with the extraction solvent also includes a circulation step, and the frequency of the circulation is 1 to 2 times per day; and / or, In the soaking extraction step, the volume concentration of the extraction solvent of the soaking mixture is 20% to 75%; and / or, The preparation method also includes the step of freeze-drying the Chinese medicine composition to obtain freeze-dried powder of the Chinese medicine composition, wherein the freeze-drying time is 8 to 24 hours, the vacuum degree is -0.10 to -0.05Mpa, and the cold trap temperature is -80 to -40°C.
8. The method for preparing the Chinese medicinal composition for improving sleep according to claim 6, characterized in that: In the heating reflux extraction step, the volume concentration of the extraction solvent added to the mixture is 30% to 95%; and / or, In the heating reflux extraction step, in a single extraction, the mass ratio of the extraction solvent added to the mixture to the mixture is (4-10):1; and / or, In the heating reflux extraction step, the single extraction time is 0.45 to 2 hours; and / or, The concentration method includes concentration under reduced pressure; and / or, The relative density of the clear paste is 1.15 to 1.25; and / or, Adding an extraction solvent to the clear paste to adjust the alcohol content of the clear paste to 20-56%, Vol; and / or, The standing time is ≥ 24h; and / or, Solid-liquid separation includes the step of filtration.
9. The Chinese medicine composition for improving sleep according to any one of claims 1 to 4 or the Chinese medicine composition prepared by the method for preparing the Chinese medicine composition for improving sleep according to any one of claims 5 to 8 has any of the following uses: (1) Preparation of foods and medicines for improving sleep and treating deficiency of Qi and blood; (2) Reversing the damage and aging of astrocytes and microglia; (3) Reversing inflammatory response; (4) Regulate circadian rhythm; (5) Reversal pathways include those related to neurodegeneration, neuroinflammation, neuronal excitation, and peripheral inflammation.
10. The use according to claim 9, characterized in that The food includes alcoholic beverages; and / or The dosage form of the drug includes at least one of capsules, tablets, granules, powders, pills, oral liquids or suspensions; and / or, The reversal pathways include at least one of the neurodegenerative pathways - multiple diseases, Alzheimer's disease, Parkinson's syndrome, neuroactive ligand-receptor interaction, cytokine-cytokine receptor interaction, cell autophagy, ATP metabolism, TNF signaling pathway, NOD-like receptor signaling, cell adhesion, cell apoptosis, and cell senescence pathways.
Citation Information
Patent Citations
Device for removing organic contaminant on artificial dental root
JP2012000118A
Pinball game machine
JP2021000320A
Preparation method and use of compound recipe spina date seed composite extract
CN110038085A
Sour poria-containing jelly with functions of sleep helping and maintaining mental tranquility and processing equipment thereof
CN111345472A
Preparation method of healthy beverage beneficial to sleep
CN111772066A
